1-20 of 25
Omid Hamid
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma

Sylvia M. Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina, Amanda Gillespie-Twardy, Inderjit Mehmi, Sunandana Chandra, Graham Watson, Patrick Ward, Marya Chaney, Hailing Lu, Jason Berndt, Brian P. O’Connor, Kapil Rathi, Eeman Shaikh, Charles Lance Cowey
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (5): 848–859.
https://doi.org/10.1158/1078-0432.CCR-24-1478
Published: 03 March 2025
View articletitled, Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Open the PDF for Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma in another window
Includes: Supplementary data
Journal Articles

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

Allison Betof Warner, Pippa G. Corrie, Omid Hamid
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1835–1854.
https://doi.org/10.1158/1078-0432.CCR-22-1922
Published: 15 May 2023
View articletitled, Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future
Open the PDF for Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future in another window
Journal Articles

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric-Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc Pelletier, Shahneen Sandhu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-22-2235
Published: 04 January 2023
View articletitled, Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Open the PDF for Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A.L.M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 71–83.
https://doi.org/10.1158/1078-0432.CCR-21-0845
Published: 01 January 2022
View articletitled, A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Open the PDF for A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers in another window
Includes: Supplementary data
Journal Articles

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil M. Steven, Thomas R. Jeffry Evans, Alan Anthoney, Alexander N. Shoushtari, Omid Hamid, Avinash Gupta, Antonella Vardeu, Emma Leach, Revashnee Naidoo, Sarah Stanhope, Sion Lewis, Jacob Hurst, Ita O’Kelly, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5869–5878.
https://doi.org/10.1158/1078-0432.CCR-20-1247
Published: 13 November 2020
View articletitled, Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Open the PDF for Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (17): 4531–4541.
https://doi.org/10.1158/1078-0432.CCR-20-0328
Published: 01 September 2020
View articletitled, Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, Anna Maria Di Giacomo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4201–4205.
https://doi.org/10.1158/1078-0432.CCR-20-1657
Published: 14 August 2020
View articletitled, Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Open the PDF for Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era in another window
Journal Articles

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Response

Omid Hamid, Rene Bruno, Marcella Fasso, Carol O'Hear, Benjamin Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2436.
https://doi.org/10.1158/1078-0432.CCR-20-0298
Published: 15 May 2020
View articletitled, Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Response
Open the PDF for Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Response in another window
Journal Articles

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 46–53.
https://doi.org/10.1158/1078-0432.CCR-18-4180
Published: 03 January 2020
View articletitled, Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Open the PDF for Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz-Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O'Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6061–6072.
https://doi.org/10.1158/1078-0432.CCR-18-3488
Published: 15 October 2019
View articletitled, Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Open the PDF for Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3220–3228.
https://doi.org/10.1158/1078-0432.CCR-18-2740
Published: 03 June 2019
View articletitled, Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Open the PDF for Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors in another window
Journal Articles

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2403–2413.
https://doi.org/10.1158/1078-0432.CCR-18-1341
Published: 15 April 2019
View articletitled, Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View articletitled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View articletitled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma

Jessica Yang, Omid Hamid, Richard D. Carvajal
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3477–3479.
https://doi.org/10.1158/1078-0432.CCR-18-0020
Published: 31 July 2018
View articletitled, The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma
Open the PDF for The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma in another window
Journal Articles

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion-Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure-Kunkel, Suba Krishnan, Holbrook Kohrt, Mario Sznol, Ronald Levy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1929–1936.
https://doi.org/10.1158/1078-0432.CCR-16-1272
Published: 13 April 2017
View articletitled, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Open the PDF for Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2289–2296.
https://doi.org/10.1158/1078-0432.CCR-14-1630
Published: 14 May 2015
View articletitled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Open the PDF for Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition in another window
Includes: Supplementary data
Journal Articles

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O'Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, Richard F. Kefford
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4449–4458.
https://doi.org/10.1158/1078-0432.CCR-14-0887
Published: 01 September 2014
View articletitled, Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Open the PDF for Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) in another window
Includes: Supplementary data
Journal Articles

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Thinle Chodon, Begoña Comin-Anduix, Bartosz Chmielowski, Richard C. Koya, Zhongqi Wu, Martin Auerbach, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Tara A. McCannel, Akira Ishiyama, Johannes Czernin, Caius G. Radu, Xiaoyan Wang, David W. Gjertson, Alistair J. Cochran, Kenneth Cornetta, Deborah J.L. Wong, Paula Kaplan-Lefko, Omid Hamid, Wolfram Samlowski, Peter A. Cohen, Gregory A. Daniels, Bijay Mukherji, Lili Yang, Jerome A. Zack, Donald B. Kohn, James R. Heath, John A. Glaspy, Owen N. Witte, David Baltimore, James S. Economou, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2457–2465.
https://doi.org/10.1158/1078-0432.CCR-13-3017
Published: 30 April 2014
View articletitled, Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Open the PDF for Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, David MacLean, Ajit Suri, Walter M. Stadler, Daniel Shevrin, Lowell Hart, Gary R. MacVicar, Omid Hamid, John Hainsworth, Mitchell E. Gross, Yuanjun Shi, Iain J. Webb, David B. Agus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (5): 1335–1344.
https://doi.org/10.1158/1078-0432.CCR-13-2436
Published: 02 March 2014
View articletitled, Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data